This is one of the great disappointments. They were very gunhoe on this, and spent at least $3m on the purchase of this product/license. There was a couple of posts on the nvdl.ob board, that suggested sales of 1.5m for the year and nearly 1m per quarter, but no support on this number (I asked on the board for the support but did not get any real info). Personally, I think NVDL.ob is going under. They seem like a bunch of guys sitting around thinking of ideas. They seem to be at the limit of drawing any moneys, and burn money at the rate of about $1m a quarter, and had less than that at the end of the last quarter. They do have some debts, although they might be debentures of other debts that are not being demanded. But when I said some of this on the nvdl.ob board, I got yelled at, even though I was wishing them the best of luck.
<<They seem like a bunch of guys sitting around thinking of ideas.>>
ECR seems to be the guys sitting around! Ambien is a $2 billion market. ECR's penetration into this huge market pathetic and lacking. Perhaps they should reconsider their marketing approach. Similar products are marketed with a zero co-pay. Zolpimist is an immense opportunity.
wouldnt be suprised to see co-pay strategy re-jiggered like NVDL did with Nitromist. No need to say sorry, actually have been buying more NVDL at these prices, mgmt and private equity is in at a 16-18cents basis, wouldnt be suprised to see a 30-40 cent trading range by year end. From 3 cents, thats a good trade, risky, but worth the risk